Contemporary Treatment of Systemic Lupus Erythematosus: an Update for Clinicians

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2012 Dec 20

PMID 23251736

Citations 30

Authors

Maame B Amissah-Arthur

Caroline Gordon

Affiliations

Soon will be listed here.

Abstract

The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.

Citing Articles

Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential.

Poznyak A, Orekhov N, Churov A, Starodubtseva I, Beloyartsev D, Kovyanova T Diseases. 2024; 12(9).

PMID: 39329895 PMC: 11430897. DOI: 10.3390/diseases12090226.

Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark.

Troldborg A, Remkus L, Eek D, Deleuran B Lupus. 2024; 33(9):962-973.

PMID: 38901042 PMC: 11348625. DOI: 10.1177/09612033241261746.

rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus.

Fajar D, Rostinawati T, Hamijoyo L, Sahiratmadja E, Amalia R, Barliana M Biologics. 2024; 18:95-106.

PMID: 38715569 PMC: 11075687. DOI: 10.2147/BTT.S452792.

A Comprehensive Review on Biofilms in Otorhinolaryngology: Understanding the Pathogenesis, Diagnosis, and Treatment Strategies.

Ghosh Moulic A, Deshmukh P, Gaurkar S Cureus. 2024; 16(4):e57634.

PMID: 38707023 PMC: 11070220. DOI: 10.7759/cureus.57634.

A Rare Case of Atypical Anti-glomerular Basement Membrane Disease.

Gupta S, Kashiv P, Sejpal K, Dubey S, Malde S, Gurjar P Cureus. 2023; 15(11):e49064.

PMID: 38125251 PMC: 10731130. DOI: 10.7759/cureus.49064.

References

Contreras G, Pardo V, LeClercq B, Lenz O, Tozman E, ONan P . Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350(10):971-80. DOI: 10.1056/NEJMoa031855. View

Tew G, Rabbee N, Wolslegel K, Hsieh H, Monroe J, Behrens T . Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2009; 19(2):146-57. DOI: 10.1177/0961203309350752. View

Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M . Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000; 9(6):401-5. DOI: 10.1191/096120300678828596. View

DallEra M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007; 56(12):4142-50. DOI: 10.1002/art.23047. View

Liossis S, Sfikakis P . Costimulation blockade in the treatment of rheumatic diseases. BioDrugs. 2004; 18(2):95-102. DOI: 10.2165/00063030-200418020-00003. View

Herishanu Y . Rituximab-induced serum sickness. Am J Hematol. 2002; 70(4):329. DOI: 10.1002/ajh.10127. View

Merrill J, Neuwelt C, Wallace D, Shanahan J, Latinis K, Oates J . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2009; 62(1):222-33. PMC: 4548300. DOI: 10.1002/art.27233. View

Flanc R, Roberts M, Strippoli G, Chadban S, Kerr P, Atkins R . Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004; 43(2):197-208. DOI: 10.1053/j.ajkd.2003.10.012. View

Leandro M, Cambridge G, Edwards J, Ehrenstein M, Isenberg D . B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005; 44(12):1542-5. DOI: 10.1093/rheumatology/kei080. View

10.

Jonsson H, Nived O, Sturfelt G, Silman A . Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol. 1990; 29(3):185-8. DOI: 10.1093/rheumatology/29.3.185. View

11.

Fortin P, Abrahamowicz M, Ferland D, Lacaille D, Smith C, Zummer M . Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008; 59(12):1796-804. DOI: 10.1002/art.24068. View

12.

Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

13.

Pons-Estel G, Alarcon G, Scofield L, Reinlib L, Cooper G . Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2009; 39(4):257-68. PMC: 2813992. DOI: 10.1016/j.semarthrit.2008.10.007. View

14.

Anderka M, Lin A, Abuelo D, Mitchell A, Rasmussen S . Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009; 149A(6):1241-8. DOI: 10.1002/ajmg.a.32685. View

15.

Roman M, Shanker B, Davis A, Lockshin M, Sammaritano L, Simantov R . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349(25):2399-406. DOI: 10.1056/NEJMoa035471. View

16.

Stillwell T, Benson Jr R, DeRemee R, McDonald T, Weiland L . Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum. 1988; 31(4):465-70. DOI: 10.1002/art.1780310402. View

17.

Ginzler E, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley M . Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2009; 62(1):211-21. DOI: 10.1002/art.25052. View

18.

DCruz D . Antimalarial therapy: a panacea for mild lupus?. Lupus. 2001; 10(3):148-51. DOI: 10.1191/096120301669779293. View

19.

Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R . European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2009; 69(7):1269-74. PMC: 2952401. DOI: 10.1136/ard.2009.117200. View

20.

Cunnane G, Chan O, Cassafer G, Brindis S, Kaufman E, Yen T . Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum. 2004; 50(5):1539-48. DOI: 10.1002/art.20147. View